Month: August 2011

Biocruces scientists identified 1,500 genes altered by the celiac gluten intolerance.

|

Biocruces scientists identified 1,500 genes altered by the intolerance to gluten gluten-free.

research genetics in the BioCruces Institute.


– the researchers of the Institute are looking for a therapy that reduces the effects of gluten in patients and that might be available in cases of exceptional, accidental intake or volunteer.

-BioCruces team has identified a gene whose modulation is able to return to normal function of the biological route.-

“ once proved the concept, are looking at the magnitude of the effect of the modulation of the biological route in control processes such as inflammation and cellular injury ” explains Dr. José Ramón Bilbao, responsible of the laboratory of Immunogenetics of BioCruces and leader of this research


Bilbao, June of 2011- research carried out by the BioCruces Institute in the field of celiac disease is bearing fruit. Vizcaíno Center scientists have succeeded in detecting more than 1500 genes altered by the intolerance to gluten for celiac patients. This project, led by the head of the laboratory of Immunogenetics of the Institute, Dr. José Ramón Bilbao, along with Leticia Plaza and Nora Fernandez, and whose main clinical researcher is Dr. Juan Carlos Vitoria, is intended to reduce the toxic effects of gluten in the gluten-free, modulating the intensity of inflammation in the gut, so reduction in symptoms associated with the ingestion of gluten.

“ is to find a complementary therapy that may be available to celíacas for cases of exceptional gluten ingestion (accidental or voluntary) ”, explains Dr. Bilbao. Therefore scientists departed that base “ there must be many genes altered by exposure to gluten, and we are dealing with your ID at the beginning of this project ”.

using expression microarrays, analysed all the genes in the genome to detect changes in function which occurred by effect of gluten, comparing biopsy of celiac patients taken to the diagnosis, they were taken after two years of diet free of gluten. “ thus identified more than 1,500 altered genes, which could group in biological processes more complex (growth and cell death, communication between cells, etc.) potentially relevant to the development of the disease ”, points Bilbao.

in one of these biological pathways, the BioCruces team has managed to identify a gene whose modulation is able to return to normal function of the biological route. The group is currently doing a more comprehensive study of all of the altered biological path and its consequences, testing the effects of modulation in exposures to different amounts and times of incubation of gluten. To do this, perform experiments with leftover debris from biopsies of celiac people and crops of cellular models of intestino delgado.

“ could say that once proved the concept, we are looking at the magnitude of the effect of the modulation of the biological route in control processes such as inflammation and cellular injury ”, outlines the leader of the research, which adds that “ is a slow process ”. In fact, BioCruces experts do not expect to test therapies on animals for two years, then start to test trials in people.



Read More

The self control of capillary glucose in type 2 diabetes diagnosis favours the recovery of the beta cell.

|

self-monitoring of blood capillary in type 2 diabetes diagnosis favours the recovery of cell beta.


-the San Carlos study shows that self-monitoring of capillary glucose accompanied by a curriculum significantly improves glycaemic control in patients with diabetes type 2 not treated with insulin.

– has been in 161 consecutive with Diabetes patients type 2 (DM2) diagnosed between 2006 and 2007 with HbA1c < 8% and ≪ 6 months from diagnosis

Madrid, June 2011.- according to data from the National Institute of statistics (INE), it is estimated that the number of adults with diabetes around the world will rise from 135 million in the year 1995 to 300 million by the year 2025. About 95% of patients who suffer from this disease they suffer from type 2 diabetes. These figures make particularly relevant the study carried out by Dr. a. Calle Pascual, and introduced the enormously June 17 in the ’ days of latest developments in Diabesidad for AP´, whose main objective was the evaluate the benefits of managing the glycemic control through self-monitoring of capillary glucose, with the use only of hemoglobin glycosylated.


key: self-monitoring of glucose capillary.

the main objective of the ’ Studio San Carlos. Benefits of self-monitoring in Diabetes type 2 of recent diagnóstico´ is the transmit to “ there is a recovery of the cell beta based on the improvement of the levels of insulin and the estimation of insulin resistance as measured by HOMA-IR, without specifying other than metformin drug ”. However, Dr. Street – author of this – explains that: “ confirm a total healing would be excessive. Right thing to would be to talk a regression of diabetes and the obtaining of blood glucose values similar to persons who do not have this condition, that, although there is a return to stages prior to the hiperglucémica phase, probably other markers could remain altered ”.

the analysed sample comprises a total of 161 consecutive DM2 patients diagnosed between 2006 and 2007 with HbA1c < 8% and ≪ 6 months from diagnosis; still included 99 of them in a group conducting self-analysis structured capillary glucose and 62 in the group control.

defined profile of self-analysis was 6 points before and two hours after the breakfast, lunch and dinner, in an attempt to reach optimum levels throughout the day. After a thorough follow-up found that structured self-analysis group achieved a higher rate of regression defined HbA1c < 6% and reference defined by HbA1c 6 to 6.4 per cent than the control group.

This shows that when using the self-monitoring of capillary glucose in patients properly “ educated ”, manages to achieve the control objectives more effectively using only the hemoglobin glycosylated.

the study provides evidence consistent on the value of SMBG structured blood capillary as an educational tool for the patient and as a tool to optimize the treatment of diabetes by the professional, allowing changes active and targeted therapy.


peculiarities of the patient DM2.

as opposed to other types of diabetes, not all patients with DM2 are forced to take medication or require insulin injections; much control your blood sugar levels simply meal planning and exercise. According to Dr. Street: “ several studies have shown an intervention based on lifestyle changes can prevent more than 50% of cases of diabetes type 2 in patients at risk for developing. Physical exercise is a crucial parameter; at least 30 minutes a day are essential for success ”.


the role of the tools for management of blood sugar.

the great technological advances of recent decades has provided tools to help in the process of registration, interpretation and transmission of data of capillary glycemia, providing support in the process of care to the diabetic patient.

according to the DRA. Pérez Ferre, who intervened ’ new technologies applied to the monitoring of the diabetes´, “ these programs of management of blood glucose data or information on glycaemia managers have emerged to help extract the most out of the automonotorización of capillary glycemia, constituting a valuable and motivating educational element to the patient, learn to identify what they see, knowing where are their difficulties and learning how to set goals ”.

occasionally there is some resistance from health professionals in the use of these computer systems because they involve a learning process and a time of prior commitment. However, they offer a wide range of possibilities for the treatment of the patient, with very specific data, structured in tables and graphs. In addition, electronic notebooks allow information traveling over the Internet, making possible the integration of telemedicine.



Read More

Presented at the World Congress of menopause last studies of hormonal treatments for vaginal atrophy.

|

Presented at the World Congress of menopause the latest studies on hormone to atrophy treatments vaginal.

Рa million and half of women in Spain suffer from symptoms associated with vaginal atrophy in its hipoestrog̩nica phase, but only one in four women consultation with your health care provider

-women complain before hot flushes and sweating that of vaginal dryness which will worsen with age if it is not treated

-vaginal atrophy affects half of all women in menopause and influences of determining how sexual functionality and their quality of life

Rome, 2011-June every three years, the international Menopause Society organizes a World Congress on menopause in trying to take stock of the latest studies and data published in the scientific literature. The 13th World Congress on menopause, held this year in Rome has hosted gynecologists experts on pathogenesis and treatment of premature menopause and osteoporosis as well as the impact of hormonal cancer, cardiovascular disease or osteoporosis treatment, the effects of menopause on the mood and the central nervous system, among other topics. Spanish participants highlighted the presence of Dr. Sanchez Borrego, President of the Spanish Association for the study of the menopause-EMEA. Dr. Sanchez Borrego has valued the important speeches made by all the professionals from Spain, most notably the submission of the studies presented by doctors Antonio Cano, Chief of the service of Gynecology and obstetrics at the Hospital Universitario Dr. Peset of Valencia and Juan Luis Delgado, attached to the service of gynaecology and obstetrics of the Hospital Universitario Virgen of the Arixaca of Murciaon the estriol formulated gel administered vaginally.

Latest data on vaginal atrophy

Vaginal atrophy is the medical term that refers to the thinning of the vaginal wall that occurs during menopause. Vaginal atrophy has undoubtedly been one of the protagonists in the World Congress of menopause as a pathology of high prevalence in women at menopause. It is estimated that approximately between 40-60% of women in menopause suffer local symptoms associated with vaginal atrophy that occurs as a result of the progressive fall of estrogen, something characteristic of this stage of the life of the woman.

A series of symptoms whose effects are very subjective depending on each woman appear in women in menopause. Although vasomotor symptoms such as hot flashes and night sweats are resolved in the majority of cases spontaneously with the passage of time (2-3 years), the symptoms associated with atrophy of the urogenital tract, and vagina worsen progressively, increasing problems and consequently the quality of life, for this reason these symptoms – such as vaginal dryness – reaching the second complaint of women in this stage of life.

Some data provided by other countries indicate that approximately 5% of all women attending a gynecological visit concern dyspareunia (pain with intercourse) in relation to vaginal dryness, a percentage that is three or four times higher in women during menopause and is known increases with the age of the woman. In general there are several discomfort associated with the field urogenital, such as incontinence or trigonitis (inflammation of the bladder triangle that forms the base of the bladder). Vaginal dryness, according to the VIVA survey is currently under the Spanish society of Gynecology and obstetrics is the vaginal symptoms most frequently referred to, is associated with dyspareunia and dysuria (pain when urinating) are problems that frequently cite the patients with menopause is defined as “ not symptomatic ” and thereforelittle treated, but that actually punishes harshly the life of relationship and affects their quality of life.

However only 1 of every 4 query for this reason despite the fact that these symptoms are usually progressive and worsen in the absence of treatment, in fact narrowed epithelium causes with the rubbing of sexual relations occurring pain accompanied by bleeding for the treatment of choice is to manage an estrogen level topical (local action and that) (no passes into the blood). “ Is important to clarify that these oestrogens have nothing to do with the controversy of estrogen at menopause, known hormone replacement therapy ” specifies Dr. Sanchez Borrego, President of the EMEA.

Effective and safe treatments

Local treatments include vaginal moisturizers which can partly alleviate these annoyances but not reverse the atróficos changes associated with menopause for what would be necessary to the use of the treatment of choice with estrogen. To treat vaginal dryness, topical hormonal treatments of estriol (estrogen weaker few produces women), it is recommended that to be an effective ingredient for local use reduces the overall absorption throughout the body and thereby consequential adverse events incidence.

The use of dose ever-lower and different from the oral routes of administration are the new perspective on the treatment of the symptoms of menopause, which is intended to increase the beneficial effects while reducing side effects.

More information about the EMEA

The EMEA is the scientific society of reference in the care of the peri- and postmenopausal women. This association aims to educate women to ask more on climacteric symptoms and professionals to make them more proactive to the complaints of his patients, in this way can reverse some of the symptoms that are most troublesome for women in menopause. Its motto in this 2011 on the basis of the international day of menopause was the of “ Vaginal health ”.

Read More

BOND and Lab21 collaborate to develop new molecular testing system BD MAX Aspergillus test

|

BD and Lab21 collaborate to develop new molecular testing system BD MAX Aspergillus test ™

BALTIMORE and CAMBRIDGE, England, August 3, 2011/PRNewswire /-

-the agreement involves a planned action leading to the menu of content-rich systems tests

BD Diagnostics, a segment of BD (Becton) global medical technology company(, Dickinson and Company) (NYSE: BDX), and Lab21, a world leader in personal health, have today announced a collaboration to develop a molecular diagnosis of last generation test to detect fungi Aspergillus, which pose a threat to life, using the fully automated molecular test BD MAX ™.

“ Potential to detect Aspergillus in blood using real-time Polymerase chain reaction is a topic of great interest for doctors, as it offers strategies for diagnosis and control more sensitive and accurate for final and primary detection of the aspergillosis ”, said Graham Mullis, Managing Director of Lab21.

Infections caused by Aspergillus is a major cause of death by infection in immunocompromised patients, and an estimated 10 million people in the world at risk each year. Studies have shown that the diagnosis of Aspergillus infection followed by an anti-fungal treatment 10 days after infection reduces mortality, from 90% to 40% – emphasizing the need for rapid and acute tests. Real-time Polymerase chain reaction could offer important advantages in the sensitivity and specificity to the current techniques of cultivation.

“ This agreement with Lab21 has been designed in order to add an innovative test to the menu of test growing system DB MAX to help doctors and professionals of the laboratories with rapid and accurate information on which to base treatment decisions important molecular ”, said Tom pollen, general director of BD Diagnostics – Diagnostic Systems. “ To collaborate with the best developers in his class of in vitro diagnostics, such as Lab21, our goal is to get the system DB MAX to be an indispensable tool in clinical laboratories, providing a menu of test growing in a fully automated platform ”.

According to pollen, BD plans carry new trials to MAX bond system in a wide range of disease categories. With this announcement, it now has more than 14 trials in the range of the menu of featured content of the system DB MAX. In combination with the ability to open, standardized workflow and full automation, the BD MAX system will enable laboratories to consolidate and standardize their molecular test to build programs that meet the current and future needs.

About BD

BD, a major global company in the medical technology develops, manufactures and sells medical devices, instrument systems and reagents. The company is dedicated to improving the health of people around the world. Bond focuses on improving therapies of drugs, improving the quality and speed of diagnosis of infectious diseases, and the advancement of research and discovery of new drugs and vaccines. The capacities of BD are instrumental to combat some of the most pressing diseases of the world. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 29,000 people in more than 50 countries around the world. The company provides its services to health institutions, researchers of the science of life, clinical laboratories, industry and public in general. If you would like more information please visit http://www.bd.com.

About Lab21

Lab21 is a global leader in personalized treatments. It provides products for diagnosis and services that support the control of the blood banks, medical diagnostics and drug discovery. Lab21 customers include international suppliers of health treatments, Diagnostics and pharmaceutical companies. Lab21 products division manufactures kits for immunological diagnosis and reagents that are distributed in international way and focus on infectious diseases for blood banks and clinical markets. Clinical Lab21 services operations include a growing test portfolio, providing company diagnosis and molecular testing of high-tech. Lab21 corporate offices are located in Cambridge, United Kingdom, and South Carolina, United States, and their manufacturing GMP site is in Cambridge, as well as with other plants for the production in Newmarket, Camberley and Bridport. Website: http://www.lab21.com

Read More

The emergence of generic HIV compromises the benefits of the co formulaciones.

|

The emergence of generic HIV compromises the benefits of the co-formulaciones.

the simplicity of this type of treatment has improved the effectiveness and adherence levels and has resulted in better quality of life for the patient, with a decline in the number of hospitalizations and a lower risk to the development of antiviral resistance.

Spain, August of 2011- the emergence of generic in the treatment of HIV infection could compromise the use of co-formulaciones, i.e. the combination of several drugs in one pill, which has been one of the great advances in terms of simplicity and compliance by the patient.

The co-formulaciones been proven effective to avoid medication errors and prevent that to be one of the drugs separately, hampering the development of resistance of the HIV virus to treatment.

The introduction of the generic of one of the included compounds would compromise the use of the co-formulaciones, which would be a “step backwards” for the quality of life of the patient, achieved thanks to the simplicity of the treatments. Thus claim it the most relevant Spanish experts group in the field of HIV, including the Dres. Josep M. Llibre, Santiago Moreno or Bonaventura Clotet, who have published their conclusions in a document of consensus in the prestigious journal AIDS.

“The emergence of generic is allowed once the original drug patent expires.” Usually it involves automatic replacement of one by another drug and is welcome to reduce the price of medicines. ’’ But in the case of the co-formulaciones, when expire the patent of only one of the included drugs, if you want to manage the new generic should “break” combination and administer drugs separately,”says El Dr. Josep María Llibre, who has led the development of the document.

Advances in research

The treatment of HIV infection has been one of the most dynamic of late 20th century research fields. Began taking 20 tablets distributed in 3-4 daily intakes, schemes a situation which greatly hindered the correct treatment compliance. The research allowed reducing the number of shots, pills and improve their tolerance. Finally, the arrival of the co-formulaciones was one of the great advances in the treatment of HIV, that the patient only needed for taking a single pill that already included different drugs, sometimes containing all the necessary treatment for the whole day. Furthermore, became apparent that the co-formulaciones also reduce the risk to the developing resistance to antiretroviral drugs.

The creation of co-formulaciones required a thorough investigation which reached the same level of safety and effectiveness in the administration of the drugs separately, avoiding at the same time you interactions between different medications. The main beneficiaries were the patients who improved their quality of life with treatments which facilitated adherence and minimizing errors.

Fewer hospital admissions

Research highlights the specific characteristics of the HIV cause that loss of adherence to result in an increased risk of hospitalization, with the impact that this represents for the health of the individual, both for the economic costs of his treatment. “Advances in co-formulación have been a cost savings derived from the improvement in adherence to treatment, reducing errors and failures of treatment, with all its consequences.” If the generic aims precisely to reduce the costs of drugs once its patent has expired, in antiretroviral co-formulaciones return to the Administration separately from the included drugs could lead to increased costs in the long term than those who seek to reduce by replacing one of the components as generic. “These costs are associated with a greater number of errors, failures, failures of treatment and finally, development of specific antiviral resistance,” says Dr. Josep M. Llibre.

Demands to the authorities and the pharmaceutical industry

Therefore, the Group of researchers, the doctors Josep M. Llibre, José r. Arribas, Pere Domingo, Josep M. Gatell, Fernando Lozano, José r. Santos, Antonio Rivero, Santiago Moreno and Bonaventura Clotet, concludes the study stating that “both health authorities and the pharmaceutical industry should be to agree to preserve the use of co-formulaciones when the introduction of a generic equivalent to one of the drugs” “including puts at risk the disintegration of his administration on different tablets”.

Perspective of the patient

According to Ferran Pujol, President of the names project NGO, “have been many years needed to be able to have a treatment appropriate, simple and compatible with everyday life.” In our case a simple error or forgetfulness may result in significant consequences on our health. And with the co-formulación we managed to minimize such risks. “Now the entry of generics is an involution which affected principals are patients”.

Research of the Spanish expert group effectively refers to several studies have shown that interruptions in treatment are associated with an increase in the occurrence of opportunistic infections and other inflammatory in this type of patient nature. At the same time, the emergence of new disorders more expensive cost and toxicity of antiretroviral drugs when administered uninterruptedly. And this happens most frequently when the treatment consists of various medications administered separately.

Co-formulaciones hypertension and TB

The reduction in the number of tablets and doses patients of chronic diseases should be handled is not news of HIV infection. It is a priority to reduce errors in the Administration and improve adherence to treatment which has already shown previously in hypertension. The American Society of hypertension has been sympathetic to the preferential use of co-formulaciones as a practice necessary to improve the effectiveness of treatments.

The treatment of tuberculosis is also another example to be taken into account. The use of co-formulaciones in this condition not only improves adherence to treatment, but it also avoids the appearance of bacterial resistance to any of the drugs administered separately. In this regard, who and the International Union against Tuberculosis and lung disease recommend the use of co-formulaciones to ensure optimal treatment and prevent the development of resistance by the causative agent of tuberculosis.

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips